HERZLIYA, Israel, and CALGARY, Alberta — Innocan Pharma Corporation publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed public offering of units in the United States.
Each Unit will be comprised of one common share of the Company and one common share purchase warrant of the Company. Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price and term in the context of the market.
Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols “INNP” and “INNPW”, respectively.
ThinkEquity is acting as sole book-running manager for the offering.
This proposed offering will be made only by means of a prospectus. Upon availability, copies of the preliminary prospectus related to the proposed offering may be obtained from ThinkEquity. The final prospectus will be filed with the SEC and will be available on the SEC’s website.
A registration statement relating to this offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Iris Bincovich, Innocan Pharma’s CEO, said, “The entire Innocan Pharma team and I are thrilled with having taken this significant step in the process of our listing on the Nasdaq, which opens up exciting new opportunities for us on multiple levels.”
About Innocan
In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary.
